Immune Checkpoint Inhibitors: Challenges and Potential Strategies

Tianyu Ge

doi:10.62051/fm44ky04

Authors

Tianyu Ge

DOI:

https://doi.org/10.62051/fm44ky04

Keywords:

Immune checkpoint inhibitors; immunotherapy; immune-related adverse events; inflammatory toxicity; combination therapy.

Abstract

With the rapid development of science and technology, the treatment of cancer is also constantly being upgraded, but the number of cancer patients continues to grow, this has led to an increasing emphasis on such diseases. Therefore, immune checkpoint inhibitors have become the focus of our research today. In tumor cell proliferation, immune checkpoints develop as one of the ways to assist tumor cells in immune escape, so the use of immune checkpoint inhibitors can activate T cells, reduce T cell function exhaustion and inability, and achieve the purpose of killing tumor cells. In recent years, the results of PD-1, PD-L1 and CTLA-4 inhibitors have also been widely used in the treatment of patients, new treatments based on these inhibitors are also emerging. Despite the success of the ICIs in some ways, however, the researchers still found a number of factors that hindered its continued development, for example, research gaps with overall low response efficiency, therefore, new treatments need to be better improved and designed. Consequently, the research topic of this paper is the problems encountered by immune checkpoint inhibitors in this field and their solutions.

Downloads

Download data is not yet available.

References

[1] World Health Organization (WHO). Global cancer burden growing, amidst mounting need for services. February 1, 2024. Retrieved from: https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services.

[2] Shiravand, Y., Khodadadi, F., Kashani, SMA. et al. Immune Checkpoint Inhibitors in Cancer Therapy. Current Oncology 29, 3044-3060 (2022).

[3] Marin-Acevedo, JA., Kimbrough, EO., Lou, YY. Next Generation of Immune Checkpoint Inhibitors and Beyond. Journal Hematology Oncology 14, 45 (2021).

[4] Amaris, N. Geisler., Gregory, S. Phillips., Dulce, M. Barrios. et al. Immune Checkpoint Inhibitor–related Dermatologic Adverse Events. Journal of the American Academy of Dermatology 83 (5), 1255-1268 (2020).

[5] Sreya, Bagchi., Robert, Yuan., Edgar, G. Engleman. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annual Review of Pathology: Mechanisms of Disease 16, 223-249 (2021).

[6] Wright, J.J., Powers, A.C., Johnson, D.B. Endocrine Toxicities of Immune Checkpoint Inhibitors. Nat Rev Endocrinol 17, 389-399 (2021).

[7] Luisa, Barrueto,. Francheska, Caminero,. Lindsay, Cash. et al. Resistance to Checkpoint Inhibition in Cancer Immunotherapy. Translational Oncology 13 (3), 100738 (2020).

[8] Brahmer, JR., Abu-Sbeih, H., Ascierto, PA. et al. Society for Immunotherapy of Cancer (SITC) Clinical Practice Guideline on Immune Checkpoint Inhibitor-related Adverse Events. Journal for Immunotherapy of Cancer 9, 34172516 (2021).

[9] Antonio Passaro et al., Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies. Journal of Clinical Oncology 40, 598-610 (2022).

[10] Kluger, HM., Tawbi, HA., Ascierto, ML. et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. Journal for Immunotherapy Cancer 8. 32238470 (2020).

[11] S. Jennifer, Wang., Stephanie, K. Dougan., Michael, Dougan. Immune mechanisms of toxicity from checkpoint inhibitors. Trends in Cancer 9, 543-553 (2023).

[12] Varayathu, Hrishi., Sarathy, Vinu., Thomas, Beulah, Elsa. et al. Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research. Frontiers in Oncology 11, (2021).